Image Credit: Canva (representational purpose only)
Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.
The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.
Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."
Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.
Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.
Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.
Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog
High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.
Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.
According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.
The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.
Also Read: Mysterious Fog Is Making Americans Sick
These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.
Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.
On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.
The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.
The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.
In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.
Credit: AI
Taiwan’s Food and Drug Administration (TFDA) has recalled of 87,360 tablets of a blood pressure medication after a specific batch failed a quality test. Health officials raised concerns, saying that the drug may not work as effectively as expected.
The recall involves Beniel F.C. Tablets 8 mg, manufactured by Synmosa Biopharma Corp. The affected batch is 2KA31, and the medicine contains benidipine hydrochloride, a drug used to treat high blood pressure.
The problem was first identified during a stability test of the drug, which found that the tablets failed to meet the required dissolution standards.
In simple terms, a dissolution test is conducted to check how a tablet breaks down and releases its active ingredient under controlled conditions.
This is an important test as a tablet has to release the medicine in the proper way for the body to absorb it and for the drug to produce its intended effect.
Also read: Blood Pressure, Heart Medicines May Boost Effectiveness Of Antidepressants, AIIMS Study Finds
Benidipine hydrochloride belongs to a group of drugs called calcium channel blockers. These medicines help lower blood pressure by relaxing and widening blood vessels. This enables the blood to flow more easily and reduces the pressure against artery walls.
That is why a problem affecting how a tablet dissolves can matter. If the active ingredient is not released into the body as expected, the medicine may not deliver its intended therapeutic effect.
Also read: Why Are More Women Under 35 Reporting Heart-Related Symptoms?
According to the TFDA, there is no immediate concern of medication shortage. Other batches of Beniel F.C. Tablets 8 mg are not affected, and the manufacturer has sufficient inventory.
Production of the drug will also not been stopped. Taiwan News reported that two other products containing the same active ingredient are also authorised for sale.
The manufacturer has been ordered to complete the recall by August 24 and submit an investigation report along with corrective and preventive measures for future production.
Patients should not stop their blood pressure medication on their own. The TFDA advised people who are concerned about their prescription to speak with their doctor about whether an alternative medicine is necessary.
The recall highlights an often overlooked part of medication safety: a medicine can contain the correct active ingredient but still fail a quality test if its physical properties affect how the drug is released. For now, the concern is focused on one specific batch, rather than the entire Beniel F.C. product line.
Credit: AP Photos
The ongoing Ebola virus disease epidemic in the Democratic Republic of Congo (DRC) is moving faster than any previous outbreak, said WHO chief Dr Tedros Adhanom Ghebreyesus.
According to official data, confirmed cases have reached 4,449, with the death toll climbing to 2,061 across five provinces and 53 health zones in the country. However, the number of uncounted cases may be far higher than the reported figure.
“It is already the second-biggest Ebola epidemic on record, and it is moving faster than any previous Ebola outbreak. At its current pace, it is on track to eclipse the West African Ebola outbreak of 2014 to 2016,” Tedros said in a briefing.
The 2014-2016 outbreak reported at least 28,000 cases and took about eight months to reach 1,000 deaths.
Tedros noted that the current “outbreak had a big head start, it is still way ahead of us, and we are playing catch-up.”
He said this even as reports showed that the disease caused by the rare Bundibugyo virus had been circulating since February and went undetected for months. The WHO declared the outbreak on May 15.
Dr Abdirahman Mahamud, WHO’s director for health emergency alert and response operations, said the agency expects the outbreak to reach its peak within six months, AP News reported.
“But ... that’s the moderate scenario,” Mahamud said. “There is a one-case scenario where this outbreak may last nine months to 12 months.”
Also read: Ebola Death Toll Tops 2,000 In DRC: New Study Reveals Likely Source Of Bundibugyo Virus Outbreak
Tedros said about 90% of all cases and 80% of deaths are in the province of Ituri, with sustained transmission in the towns of Bunia, Rwampara, Nizi and Lita.
“Most concerningly, we see a high proportion of deaths in communities instead of treatment units, outside of known contact lists,” Tedros said.
“That tells us there are chains of transmission we don’t know about, and until we know about – and break – every chain of transmission, we will not stop the outbreak.”
Most transmission happens when people have late-stage disease and are not in treatment, or when their bodies are handled after death.
Early clinical care and safe and dignified burials are therefore critical for interrupting transmission. Both depend on the trust of affected communities, making community engagement and ownership essential.
“There is no other way,” Tedros said, adding that the response is now being scaled up, with the primary goal of interrupting transmission.
With partners, WHO is mapping and pooling resources to strengthen community-based surveillance, bring every suspected case into care and reach the 95% contact-tracing target needed to interrupt transmission. Currently, the rate is around 80%.
Read More: Ebola Outbreak: Officials To Probe Whether Bundibugyo Virus Is Mutating
Credit: iStock
American drugmaker Eli Lilly has sued six companies in the US over the alleged illegal sale of its experimental weight-loss drug retatrutide.
In a statement, Lilly said that the lawsuits target US entities allegedly selling illegal retatrutide products, claiming that their products are for “research use only” while allegedly marketing them for human use. These include
“Retatrutide is being rigorously studied as part of a comprehensive clinical trial development program,” said David A. Hyman, Lilly’s chief medical officer.
“We take the responsibility of evaluating the safety and efficacy of our investigational medicines seriously. What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk,” he added.
Lilly has filed lawsuits against:
Lilly said it has referred more than 200 individuals and entities to the US Food and Drug Administration (FDA), the US Department of Justice, state attorneys general, law enforcement agencies and professional licensing boards.
The company is also working with regulators, law enforcement and customs authorities worldwide to address the illegal market.
Lilly urged social media and e-commerce platforms, credit card companies, payment processors, and shipping and logistics companies used by sellers to help protect patients and tackle the illicit activity.
The drugmaker noted that it has reported more than 14,000 websites, advertisements, social media posts and product listings that allegedly market retatrutide unlawfully across more than 100 countries to internet service providers, social media platforms and e-commerce companies.
The US FDA has made clear that selling unapproved retatrutide directly to consumers is illegal. Retatrutide also cannot be lawfully compounded.
The FDA has warned that so-called “research-use only” products are of unknown quality and may pose risks to consumers’ health.
Black-market sellers and businesses posing as legitimate medical providers have openly marketed retatrutide as a weight-loss “hack.”
According to Lilly, such products are frequently made by unregulated foreign manufacturers. Regulators, customs agencies and law enforcement authorities worldwide have warned about these products and have taken actions including raiding clandestine manufacturing sites, seizing shipments and making arrests.
Retatrutide is one of Eli Lilly’s next-generation obesity treatments and is currently under development. Unlike Lilly’s currently approved GLP-1 drugs, retatrutide activates three hormone receptors: GLP-1, GIP and glucagon.
Researchers believe this triple-action approach could help people lose excess weight by reducing appetite while also increasing energy expenditure.
Retatrutide has attracted significant interest after late-stage clinical trials showed some of the highest weight-loss outcomes reported with an obesity medication. In Phase 3 studies, adults without diabetes who received the highest dose lost more than 28% of their body weight over 80 weeks.
Lilly plans to submit retatrutide for approval to the US FDA in the first quarter of 2027.
© 2024 Bennett, Coleman & Company Limited